Investors
Corporate Profile
Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.
Presentations
DateTitle
09/07/16
Dimension Therapeutics Corporate Presentation September 2016
Download Documentation
PDF
Stock
DMTX (Common Stock) $7.99 + 0.08 (1.01%)
High $8.50
Events
Dimension Therapeutics, Inc. 2016 Wells Fargo Healthcare Conference
09/08/16 3:30 p.m. ET
E-mail Alerts
Sign up to receive
E-mail Alerts
 
News
August 24, 2016
Dimension Therapeutics Announces Participation in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that Dimension’s CEO Annalisa Jenkins, MBBS, MRCP, will participate in two upcoming investor conferences: Citi's 11th Annual Biotech Conference Panel: Gene Therapy: A New Era Wednesday, September 7, 2016 at 1:00 p.m. Eastern Time Th[...]  Read More /
August 11, 2016
Dimension Therapeutics Reports Recent Corporate Progress and Second Quarter 2016 Financial Results
Ongoing Phase 1/2 trial DTX101 for hemophilia B clinical data expected later this year Lead IMD program, DTX301 for OTC deficiency, progressing toward IND filing Advancing broad inherited metabolic disease (IMD) portfolio with programs addressing citrullinemia type 1, phenylketonuria (PKU), and Wilson disease; activities supporting candidate selection ongoing CAMBRIDGE, Mass., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advanci[...]  Read More /
August 02, 2016
Dimension Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference
CAMBRIDGE, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that Dimension’s CEO Annalisa Jenkins, MBBS, FRCP, will present at the Canaccord Genuity 36th Annual Growth Conference on Thursday, August 11, 2016 at 12:30 p.m. Eastern Time. The conference will be held at the InterContinental Boston Hotel i[...]  Read More /
Data provided by Nasdaq. Minimum 15 minutes delayed.